| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome |
|
Medicine details |
|
| Medicine name | ravulizumab (Ultomiris®) |
| Formulation | 300 mg concentrate for solution for infusion |
| Reference number | 3920 |
| Indication | Treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab |
| Company | Alexion Pharma UK Ltd |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/08/2020 |
| NICE guidance | TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome |